MOVENTIG approved in the EU for OIC

MOVENTIG® APPROVED IN THE EUROPEAN UNION FOR
OPIOID-INDUCED CONSTIPATION

First in class treatment approved for adult patients with opioid-induced
constipation who have had an inadequate response to laxatives

AstraZeneca today announced that MOVENTIG® (naloxegol) has been granted
Marketing Authorisation by the European Commission (EC) for the treatment of
opioid-induced constipation (OIC) in adult patients who have had an inadequate
response to laxative(s). MOVENTIG is the first once-daily oral peripherally
-acting mu-opioid receptor antagonist (PAMORA) to be approved in the European
Union (EU).

Opioids play an important role in chronic pain relief and work by binding to mu
-receptors in the central nervous system, but they also bind to mu-receptors in
the gastrointestinal tract, which can result in patients suffering from OIC.

Briggs Morrison, Executive Vice President, Global Medicines Development & Chief
Medical Officer, AstraZeneca, said: "Constipation is one of the most common side
effects for those using opioid pain medication. We're very pleased to have
received marketing authorisation for MOVENTIG, as it allows us to offer a new
treatment option for the millions of patients across Europe who suffer from
opioid-induced constipation and haven't responded to laxatives."

The approval of MOVENTIG was based on data from the KODIAC clinical programme,
which was comprised of four studies: KODIAC-4, -5, -7 and -8. KODIAC-4 and -5
were both placebo controlled, double-blind, 12 week studies assessing safety and
efficacy, while KODIAC-7 was a 12 week safety extension to KODIAC-4, and KODIAC
-8 was a 52 week open label, long-term safety study.

The EC marketing authorisation applies to all member states of the EU, Iceland,
Norway and Lichtenstein. Today's announcement follows the
approval (http://www.astrazeneca.com/Media/Press-releases/Article/20140916--fda
-approves-movantik-tablets) on 16 September 2014 of MOVANTIKTM (naloxegol)
tablets by the US Food and Drug Administration, as the first once-daily PAMORA
for the treatment of OIC in adult patients with chronic non-cancer pain.

About MOVENTIG® (naloxegol)

MOVENTIG is a peripherally-acting mu-opioid receptor antagonist (PAMORA)
specifically designed for the treatment of opioid-induced constipation (OIC) in
adult patients on prescription opioid pain medicines. In Phase III clinical
studies, MOVENTIG was administered as a once-daily tablet and was designed to
block the binding of opioids to opioid receptors in tissues such as the
gastrointestinal (GI) tract.

The KODIAC clinical programme was comprised of four studies: KODIAC-4, -5, -7
and -8. KODIAC-4 and -5 were identically designed, placebo controlled, double
-blind, 12 week studies assessing safety and efficacy, while KODIAC-7 was a 12
week safety extension to KODIAC-4, and KODIAC-8 was a 52 week long-term safety
study.

MOVENTIG is part of the exclusive worldwide licence agreement announced on 21
September 2009 between AstraZeneca and Nektar Therapeutics. MOVENTIG was
developed using Nektar's oral small molecule polymer conjugate technology.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Esra Erkal-Paler    +44 20 7604 8030 (UK/Global)
Vanessa Rhodes   +44 20 7604 8037 (UK/Global)
Ayesha Bharmal    +44 20 7604 8034 (UK/Global)
Jacob Lund            +46 8 553 260 20 (Sweden)

Investor Enquiries
Thomas Kudsk Larsen                  +44 20 7604 8199    mob: +44 7818
524185
Karl Hård                                     +44 20 7604 8123  mob: +44 7789
654364
Eugenia Litz                                +44 20 7604 8233     mob: +44 7884
735627
Christer Gruvris                            +44 20 7604 8126     mob: +44 7827
836825

9 December 2014

-ENDS-